Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Authorities Mull New Steps, Probe Over Olmutinib Events

Executive Summary

Additional safety measures including a possible sales suspension are to be discussed by a review committee in South Korea on Oct. 4 that will help decide the fate of Hanmi’s EGFR inhibitor olmutinib. Financial authorities in the country are also launching a probe into the timing of the disclosure of several cases of serious adverse events with the drug.

Advertisement

Related Content

Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Korea To Limit Olmutinib Usage, Monitor All Patients
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel